| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.042 | 0.8 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.035 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |